Skip to main content
Top

Open Access 03-02-2025 | Type 1 Diabetes | Original Article

HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment

Authors: Yuta Yamamoto, Katsuya Narumi, Naoko Yamagishi, Yasunori Yonejima, Ken Iseki, Masaki Kobayashi, Yoshimitsu Kanai

Published in: Acta Diabetologica

Login to get access

Abstract

Aims

The oral administration of linoleic acid immediately before glucose tolerance test (OGTT) ameliorated postprandial hyperglycemia via GPR120 pathway in normal and type 1 diabetes (T1DM) rats. Linoleic acid could promote inflammatory mediators, but 10-hydroxy-cis-12-octadecenoic acid (HYA) converted from linoleic acid by Lactobacillus plantarum has higher GPR120 agonistic activity without promoting inflammatory mediators. This study examined whether the oral-administration of HYA immediately before OGTT also ameliorated the postprandial hyperglycemia in normal rats and T1DM rats injected with bolus insulin.

Methods

Normal and T1DM male Sprague-Dawley rats received HYA immediately before OGTT. Other T1DM rats were given HYA and Humulin R immediately before OGTT. We measured the concentration of glucose, insulin, glucagon-like peptide 1 (GLP-1) and cholecystokinin in blood before and after OGTT. We also measured the amount of glucose in the gastric tract after OGTT, and the amount of uptake of methyl-α-D-glucopyranoside in CACO-2 cells.

Results

Postprandial hyperglycemia was ameliorated by HYA in normal rats, and the postprandial blood glucose levels were slowly elevated by HYA in the T1DM model rats. HYA partially inhibited the uptake of methyl-α-D-glucopyranoside in CACO-2 cells. HYA slowed gastric motility and increased the plasma GLP-1 and cholecystokinin levels in normal rats. HYA also ameliorated the postprandial hyperglycemia in T1DM rats given bolus insulin.

Conclusion

Oral administration of HYA immediately before OGTT ameliorated postprandial hyperglycemia through inhibition of glucose absorption and slowing of gastric motility in normal rats. Furthermore, this beneficial effect of HYA was also revealed in T1DM rats injected with bolus insulin.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M (2020) Free fatty acid receptors in health and disease. Physiol Rev 100:171–210CrossRefPubMed Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M (2020) Free fatty acid receptors in health and disease. Physiol Rev 100:171–210CrossRefPubMed
2.
3.
go back to reference Miyamoto J, Igarashi M, Watanabe K, Karaki SI, Mukouyama H, Kishino S, Li X, Ichimura A, Irie J, Sugimoto Y, Mizutani T, Sugawara T, Miki T, Ogawa J, Drucker DJ, Arita M, Itoh H, Kimura I (2019) Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat Commun 10:4007CrossRefPubMedPubMedCentral Miyamoto J, Igarashi M, Watanabe K, Karaki SI, Mukouyama H, Kishino S, Li X, Ichimura A, Irie J, Sugimoto Y, Mizutani T, Sugawara T, Miki T, Ogawa J, Drucker DJ, Arita M, Itoh H, Kimura I (2019) Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat Commun 10:4007CrossRefPubMedPubMedCentral
4.
go back to reference Yamamoto Y, Narumi K, Yamagishi N, Nishi T, Ito T, Iseki K, Kobayashi M, Kanai Y (2023) Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. Front Pharmacol 14:1197743CrossRefPubMedPubMedCentral Yamamoto Y, Narumi K, Yamagishi N, Nishi T, Ito T, Iseki K, Kobayashi M, Kanai Y (2023) Oral administration of linoleic acid immediately before glucose load ameliorates postprandial hyperglycemia. Front Pharmacol 14:1197743CrossRefPubMedPubMedCentral
5.
6.
go back to reference Ogawa J, Kishino S, Ando A, Sugimoto S, Mihara K, Shimizu S (2005) Production of conjugated fatty acids by lactic acid bacteria. J Biosci Bioeng 100:355–364CrossRefPubMed Ogawa J, Kishino S, Ando A, Sugimoto S, Mihara K, Shimizu S (2005) Production of conjugated fatty acids by lactic acid bacteria. J Biosci Bioeng 100:355–364CrossRefPubMed
7.
go back to reference Miyamoto J, Mizukure T, Park SB, Kishino S, Kimura I, Hirano K, Bergamo P, Rossi M, Suzuki T, Arita M, Ogawa J, Tanabe S (2015) A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem 290:2902–2918CrossRefPubMed Miyamoto J, Mizukure T, Park SB, Kishino S, Kimura I, Hirano K, Bergamo P, Rossi M, Suzuki T, Arita M, Ogawa J, Tanabe S (2015) A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway. J Biol Chem 290:2902–2918CrossRefPubMed
8.
go back to reference Ikeguchi S, Izumi Y, Kitamura N, Kishino S, Ogawa J, Akaike A, Kume T (2018) Inhibitory effect of the gut microbial linoleic acid metabolites, 10-oxo-trans-11-octadecenoic acid and 10-hydroxy-cis-12-octadecenoic acid, on BV-2 microglial cell activation. J Pharmacol Sci 138:9–15CrossRefPubMed Ikeguchi S, Izumi Y, Kitamura N, Kishino S, Ogawa J, Akaike A, Kume T (2018) Inhibitory effect of the gut microbial linoleic acid metabolites, 10-oxo-trans-11-octadecenoic acid and 10-hydroxy-cis-12-octadecenoic acid, on BV-2 microglial cell activation. J Pharmacol Sci 138:9–15CrossRefPubMed
10.
go back to reference Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–196CrossRefPubMed Gorboulev V, Schurmann A, Vallon V, Kipp H, Jaschke A, Klessen D, Friedrich A, Scherneck S, Rieg T, Cunard R, Veyhl-Wichmann M, Srinivasan A, Balen D, Breljak D, Rexhepaj R, Parker HE, Gribble FM, Reimann F, Lang F, Wiese S, Sabolic I, Sendtner M, Koepsell H (2012) Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 61:187–196CrossRefPubMed
11.
12.
go back to reference Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM (2013) LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345:250–259CrossRefPubMed Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, Mseeh F, Shadoan MK, Sands A, Zambrowicz B, Ding ZM (2013) LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 345:250–259CrossRefPubMed
13.
go back to reference Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM (2017) LX2761, a sodium/glucose cotransporter 1 inhibitor restricted to the intestine, improves glycemic control in mice. J Pharmacol Exp Ther 362:85–97CrossRefPubMed Powell DR, Smith MG, Doree DD, Harris AL, Greer J, DaCosta CM, Thompson A, Jeter-Jones S, Xiong W, Carson KG, Goodwin NC, Harrison BA, Rawlins DB, Strobel ED, Gopinathan S, Wilson A, Mseeh F, Zambrowicz B, Ding ZM (2017) LX2761, a sodium/glucose cotransporter 1 inhibitor restricted to the intestine, improves glycemic control in mice. J Pharmacol Exp Ther 362:85–97CrossRefPubMed
14.
go back to reference Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P (2015) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38:1181–1188CrossRefPubMedPubMedCentral Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P (2015) Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 38:1181–1188CrossRefPubMedPubMedCentral
15.
go back to reference Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N (2017) Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97:411–463CrossRefPubMed Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N (2017) Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97:411–463CrossRefPubMed
16.
go back to reference Huang WK, Xie C, Young RL, Zhao JB, Ebendorff-Heidepriem H, Jones KL, Rayner CK, Wu TZ (2020) Development of innovative tools for investigation of nutrient-gut interaction. World J Gastroenterol 26:3562–3576CrossRefPubMedPubMedCentral Huang WK, Xie C, Young RL, Zhao JB, Ebendorff-Heidepriem H, Jones KL, Rayner CK, Wu TZ (2020) Development of innovative tools for investigation of nutrient-gut interaction. World J Gastroenterol 26:3562–3576CrossRefPubMedPubMedCentral
17.
go back to reference Wang X, Xie C, Marathe CS, Malbert CH, Horowitz M, Jones KL, Rayner CK, Sun Z, Wu T (2020) Disparities in gastric emptying and postprandial glycaemia between Han Chinese and caucasians with type 2 diabetes. Diabetes Res Clin Pract 159:107951CrossRefPubMed Wang X, Xie C, Marathe CS, Malbert CH, Horowitz M, Jones KL, Rayner CK, Sun Z, Wu T (2020) Disparities in gastric emptying and postprandial glycaemia between Han Chinese and caucasians with type 2 diabetes. Diabetes Res Clin Pract 159:107951CrossRefPubMed
18.
go back to reference Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M (2018) Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 53:1429–1432CrossRefPubMed Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M (2018) Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 53:1429–1432CrossRefPubMed
19.
go back to reference Thivolet C, Marchand L, Chikh K (2019) Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. Diabetologia 62:593–597CrossRefPubMed Thivolet C, Marchand L, Chikh K (2019) Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide. Diabetologia 62:593–597CrossRefPubMed
20.
go back to reference Lamos EM, Hedrington M, Davis SN (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf 18:691–701CrossRefPubMed Lamos EM, Hedrington M, Davis SN (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opin Drug Saf 18:691–701CrossRefPubMed
21.
go back to reference Stein SA, Lamos EM, Davis SN (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 12:153–175CrossRefPubMed Stein SA, Lamos EM, Davis SN (2013) A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 12:153–175CrossRefPubMed
22.
go back to reference Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S (2012) A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696:194–202CrossRefPubMed Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S (2012) A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. Eur J Pharmacol 696:194–202CrossRefPubMed
24.
go back to reference Edwards K, Li X, Lingvay I (2023) Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J Clin Endocrinol Metab 108:920–930CrossRefPubMed Edwards K, Li X, Lingvay I (2023) Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study. J Clin Endocrinol Metab 108:920–930CrossRefPubMed
25.
go back to reference Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358:94–102CrossRefPubMed Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358:94–102CrossRefPubMed
26.
go back to reference Adeghate JO, D’souza C, Kántor O, Tariq S, Souid AK, Adeghate E (2021) Early (5-day) onset of diabetes mellitus causes degeneration of photoreceptor cells, overexpression of incretins, and increased cellular bioenergetics in rat retina. Cells 10:1981CrossRefPubMedPubMedCentral Adeghate JO, D’souza C, Kántor O, Tariq S, Souid AK, Adeghate E (2021) Early (5-day) onset of diabetes mellitus causes degeneration of photoreceptor cells, overexpression of incretins, and increased cellular bioenergetics in rat retina. Cells 10:1981CrossRefPubMedPubMedCentral
27.
go back to reference Chiu CJ, Taylor A (2011) Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res 30:18–53CrossRefPubMed Chiu CJ, Taylor A (2011) Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res 30:18–53CrossRefPubMed
28.
go back to reference Dludla PV, Nkambule BB, Cirilli I, Marcheggiani F, Mabhida SE, Ziqubu K, Ntamo Y, Jack B, Nyambuya TM, Hanser S, Mazibuko-Mbeje SE (2022) Capsaicin, its clinical significance in patients with painful diabetic neuropathy. Biomed Pharmacother 153:113439CrossRefPubMed Dludla PV, Nkambule BB, Cirilli I, Marcheggiani F, Mabhida SE, Ziqubu K, Ntamo Y, Jack B, Nyambuya TM, Hanser S, Mazibuko-Mbeje SE (2022) Capsaicin, its clinical significance in patients with painful diabetic neuropathy. Biomed Pharmacother 153:113439CrossRefPubMed
29.
go back to reference Mohd Nor NA, Budin SB, Zainalabidin S, Jalil J, Sapian S, Jubaidi FF, Mohamad Anuar NN (2022) The role of polyphenol in modulating associated genes in diabetes-induced vascular disorders. Int J Mol Sci 23:6396CrossRefPubMedPubMedCentral Mohd Nor NA, Budin SB, Zainalabidin S, Jalil J, Sapian S, Jubaidi FF, Mohamad Anuar NN (2022) The role of polyphenol in modulating associated genes in diabetes-induced vascular disorders. Int J Mol Sci 23:6396CrossRefPubMedPubMedCentral
30.
go back to reference Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase HP (2010) Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 12:173–177CrossRefPubMed Cobry E, McFann K, Messer L, Gage V, VanderWel B, Horton L, Chase HP (2010) Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 12:173–177CrossRefPubMed
31.
go back to reference Luijf YM, van Bon AC, Hoekstra JB, Devries JH (2010) Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 33:2152–2155CrossRefPubMedPubMedCentral Luijf YM, van Bon AC, Hoekstra JB, Devries JH (2010) Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 33:2152–2155CrossRefPubMedPubMedCentral
Metadata
Title
HYA ameliorated postprandial hyperglycemia in type 1 diabetes model rats with bolus insulin treatment
Authors
Yuta Yamamoto
Katsuya Narumi
Naoko Yamagishi
Yasunori Yonejima
Ken Iseki
Masaki Kobayashi
Yoshimitsu Kanai
Publication date
03-02-2025
Publisher
Springer Milan
Published in
Acta Diabetologica
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-025-02459-6

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more